Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management-Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine

L. Koklesova, J. Jakubikova, D. Cholujova, M. Samec, A. Mazurakova, M. Šudomová, M. Pec, STS. Hassan, K. Biringer, D. Büsselberg, T. Hurtova, O. Golubnitschaja, P. Kubatka

. 2023 ; 14 (-) : 1121950. [pub] 20230323

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23010126

Cancer causes many deaths worldwide each year, especially due to tumor heterogeneity leading to disease progression and treatment failure. Targeted treatment of heterogeneous population of cells - cancer stem cells is still an issue in protecting affected individuals against associated multidrug resistance and disease progression. Nanotherapeutic agents have the potential to go beyond state-of-the-art approaches in overall cancer management. Specially assembled nanoparticles act as carriers for targeted drug delivery. Several nanodrugs have already been approved by the US Food and Drug Administration (FDA) for treating different cancer types. Phytochemicals isolated from plants demonstrate considerable potential for nanomedical applications in oncology thanks to their antioxidant, anti-inflammatory, anti-proliferative, and other health benefits. Phytochemical-based NPs can enhance anticancer therapeutic effects, improve cellular uptake of therapeutic agents, and mitigate the side effects of toxic anticancer treatments. Per evidence, phytochemical-based NPs can specifically target CSCs decreasing risks of tumor relapse and metastatic disease manifestation. Therefore, this review focuses on current outlook of phytochemical-based NPs and their potential targeting CSCs in cancer research studies and their consideration in the framework of predictive, preventive, and personalized medicine (3PM).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010126
003      
CZ-PrNML
005      
20240207143527.0
007      
ta
008      
230707e20230323sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2023.1121950 $2 doi
035    __
$a (PubMed)37033601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Koklesova, Lenka $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
245    10
$a Phytochemical-based nanodrugs going beyond the state-of-the-art in cancer management-Targeting cancer stem cells in the framework of predictive, preventive, personalized medicine / $c L. Koklesova, J. Jakubikova, D. Cholujova, M. Samec, A. Mazurakova, M. Šudomová, M. Pec, STS. Hassan, K. Biringer, D. Büsselberg, T. Hurtova, O. Golubnitschaja, P. Kubatka
520    9_
$a Cancer causes many deaths worldwide each year, especially due to tumor heterogeneity leading to disease progression and treatment failure. Targeted treatment of heterogeneous population of cells - cancer stem cells is still an issue in protecting affected individuals against associated multidrug resistance and disease progression. Nanotherapeutic agents have the potential to go beyond state-of-the-art approaches in overall cancer management. Specially assembled nanoparticles act as carriers for targeted drug delivery. Several nanodrugs have already been approved by the US Food and Drug Administration (FDA) for treating different cancer types. Phytochemicals isolated from plants demonstrate considerable potential for nanomedical applications in oncology thanks to their antioxidant, anti-inflammatory, anti-proliferative, and other health benefits. Phytochemical-based NPs can enhance anticancer therapeutic effects, improve cellular uptake of therapeutic agents, and mitigate the side effects of toxic anticancer treatments. Per evidence, phytochemical-based NPs can specifically target CSCs decreasing risks of tumor relapse and metastatic disease manifestation. Therefore, this review focuses on current outlook of phytochemical-based NPs and their potential targeting CSCs in cancer research studies and their consideration in the framework of predictive, preventive, and personalized medicine (3PM).
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Jakubikova, Jana $u Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u Centre for Advanced Material Application, Slovak Academy of Sciences, Bratislava, Slovakia
700    1_
$a Cholujová, Dana $u Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u Centre for Advanced Material Application, Slovak Academy of Sciences, Bratislava, Slovakia $7 xx0313639
700    1_
$a Samec, Marek $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Mazurakova, Alena $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Šudomová, Miroslava $u Museum of Literature in Moravia, Rajhrad, Czech Republic
700    1_
$a Pec, Martin $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Hassan, Sherif T S $u Department of Applied Ecology, Faculty of Environmental Sciences, Czech University of Life Sciences Prague, Prague, Czech Republic
700    1_
$a Biringer, Kamil $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Büsselberg, Dietrich $u Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar
700    1_
$a Hurtová, Tatiana, $u Department of Dermatology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Martin, Slovakia $d 1989- $7 xx0306712
700    1_
$a Golubnitschaja, Olga $u Predictive, Preventive, Personalised (3P) Medicine, Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 14 (20230323), s. 1121950
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37033601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20240207143523 $b ABA008
999    __
$a ok $b bmc $g 1958641 $s 1196390
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1121950 $e 20230323 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20230707
Back

Find record

Citation metrics

Archiving options